Effectiveness and Safety of Contemporary Drug Regimens for Multidrug- and Extensively Drug-resistant Tuberculosis in Children and Adolescents
Wamaka Kaminyoge, Reuben Simfukwe, Mwiza Singini, Norman Sitali, Felix P. Chilunga · 2026
Read Effectiveness and Safety of Contemporary Drug Regimens for Multidrug- and Extensively Drug-resistant Tuberculosis in Children and Adolescents by Wamaka Kaminyoge, Reuben Simfukwe, Mwiza Singini, Norman Sitali, Felix P. Chilunga (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13649270.txt.
Description
Drug-resistant tuberculosis is hard enough to treat in adults; in children the evidence base is thin, since most regimen data come from grown patients. Wamaka Kaminyoge and co-authors pool the world literature on modern regimens for multidrug- and extensively drug-resistant TB in patients under twenty. Their search found fourteen studies with 490 children across thirteen countries, published from 2015 to 2025.
Treatment succeeded in 89 percent of the children overall. Newer all-oral regimens, built on bedaquiline and delamanid, did slightly better at 91 percent than older ones with injectable drugs, at 83 percent. Severe side effects appeared in about 21 percent, most often a heart rhythm change and anemia, though reports were sparse and rarely pinned on one drug. The authors call the newer regimens effective and generally well tolerated, while noting their full safety picture is still incomplete.
Catalog record
| CREATOR | Wamaka Kaminyoge, Reuben Simfukwe, Mwiza Singini, Norman Sitali, Felix P. Chilunga |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |